LEADER 04593nam 22008775 450 001 9910886383903321 005 20240318103733.0 010 $a0-7748-3386-6 024 7 $a10.59962/9780774833868 035 $a(CKB)3710000001400363 035 $a(MiAaPQ)EBC4873385 035 $a(DE-B1597)661449 035 $a(DE-B1597)9780774833868 035 $a(EXLCZ)993710000001400363 100 $a20230808h20172017 uy n 101 0 $aeng 135 $aur||#|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aHealth Advocacy, Inc. $eHow Pharmaceutical Funding Changed the Breast Cancer Movement /$fSharon Batt 210 1$aVancouver, BC :$cUniversity of British Columbia Press,$d[2017] 210 4$dİ2017 215 $a1 online resource (396 p.) 311 $a0-7748-3384-X 327 $tFront Matter --$tContents --$tAcknowledgments --$tPreface --$tIntroduction --$tCanada?s Health Care System Transformed --$tCanada?s Health Policy Landscape --$tHealth Advocacy Organizations in Canada --$tFrom Grassroots to Contestation to Partnership --$tBeginnings of the Breast Cancer Movement --$tAdvocacy Redefined --$tThe Movement Fractures over Pharma Funding --$tPharma Funding as the New Norm --$tAdvocacy Groups and the Continuing Struggle over the Pharma-Funding Question --$tConclusion --$tAppendix --$tNotes --$tIndex 330 $aOver the past several decades, a gradual reduction in state funding has pressured patient groups into forming private-sector partnerships, raising an important ethical question: do these alliances ultimately lead to policies that are counter to the public interest? Health activist, scholar, and cancer survivor Sharon Batt examines the issue by investigating Canada?s breast cancer movement from 1990 to 2010. Health Advocacy, Inc. dissects the relationship between the companies that sell pharmaceuticals and the individuals who use them, drawing links between neoliberalism and corporate financing and the ensuing threat to the public health care system. Combining archival analysis, interviews with advocacy and industry representatives, and personal observation, Batt argues that the resulting power imbalance continues to challenge the groups? ability to put patients? interests ahead of those of the funders. A movement that once encouraged democratic participation in the development of health policy now eerily echoes the demands of the pharmaceutical industry. Batt?s thorough account of this shift defines the stakes of activism in public health today. 606 $aPatient advocacy$zCanada 606 $aBreast$xCancer$xResearch$zCanada$xFinance 606 $aPharmaceutical industry$zCanada 606 $aMedical policy$zCanada 606 $aPatient Advocacy$xhistory 606 $aBreast Neoplasms 606 $aDrug Industry$xhistory 606 $aDrug Industry$xeconomics 606 $aPharmaceutical Research$xeconomics 606 $aHealth Policy 606 $aPatients$xDroits$zCanada 606 $aPatients$xDroits$zCanada$xFinances 606 $aSein$xCancer$xPatients$zCanada 606 $aIndustrie pharmaceutique$zCanada 606 $aPolitique sanitaire$zCanada 606 $aBreast$xCancer$xResearch$xFinance$2fast$3(OCoLC)fst00838308 606 $aMedical policy$2fast$3(OCoLC)fst01014505 606 $aPatient advocacy$2fast$3(OCoLC)fst01055001 606 $aPharmaceutical industry$2fast$3(OCoLC)fst01060129 607 $aCanada 607 $aCanada$2fast 615 0$aPatient advocacy 615 0$aBreast$xCancer$xResearch$xFinance. 615 0$aPharmaceutical industry 615 0$aMedical policy 615 12$aPatient Advocacy$xhistory. 615 12$aBreast Neoplasms. 615 22$aDrug Industry$xhistory. 615 22$aDrug Industry$xeconomics. 615 22$aPharmaceutical Research$xeconomics. 615 22$aHealth Policy. 615 6$aPatients$xDroits 615 6$aPatients$xDroits$xFinances. 615 6$aSein$xCancer$xPatients 615 6$aIndustrie pharmaceutique 615 6$aPolitique sanitaire 615 7$aBreast$xCancer$xResearch$xFinance. 615 7$aMedical policy. 615 7$aPatient advocacy. 615 7$aPharmaceutical industry. 676 $a362.10971 686 $acoll13$2local/lacc 700 $aBatt$b Sharon$4aut$4http://id.loc.gov/vocabulary/relators/aut$01769931 801 0$bDE-B1597 801 1$bDE-B1597 906 $aBOOK 912 $a9910886383903321 996 $aHealth Advocacy, Inc$94245129 997 $aUNINA